In this issue, The HQ focuses on the continuously emerging COVID-19 variants. As mutations continue to arise and the spread of the virus is still prevalent, vaccine roll-outs with desired herd immunity to end the pandemic is still far from sight. Esco anticipates the need for scale-up solutions in providing leading-edge technologies to support stakeholders in producing top-of-the-line quality vaccines.
